Anavex Strongly focused
  on increasing value
HOME  |  ABOUT US  |  PIPELINE  |  R & D  |  PUBLICATIONS  |  PARTNERING  |  INVESTORS  |  CAREERS  |  CONTACT

Stock Quote
Share Information
Press Releases
SEC Filings
Code of Conduct
Investor Kit
Biopharma Industry
Media
 
Investors

Thank you for taking the time to learn more about Anavex Life Sciences Corp. (OTCBB: AVXL). Anavex is a specialty pharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer. We have made significant strides using our proprietary SIGMACEPTOR™ drug discovery platform and our lead drug candidate, ANAVEX 2-73, successfully completed a Phase 1 clinical trial in November 2011. This was a significant milestone for our company. With the successful completion of this trial Anavex will immediately begin a multiple ascending dose trial. We eagerly anticipate the results and look forward to announcing complete results later this year. These Phase 1 studies take us an important step closer to Phase 2 trials in patients with Alzheimer’s Disease (AD).

ANAVEX 2-73 is the first of a new class of oral drugs being studied to potentially treat AD through disease modification rather than focusing only on symptomatic improvement. Our innovative approach tackles potential upstream causes of Alzheimer’s Disease. Preclinical testing on animals generated promising results, including anti-amnesic effects, potent neuroprotective activity, excellent safety and encouraging signs of efficacy.

In January 2011, ANAVEX 2-73 was recognized by the independent publication Alzheimer’s Weekly as “The number one most promising drug in Alzheimer’s Disease” after their analysis of more than 100 trials that treat dementias and following the review of more than 10,000 articles. The editorial staff and clinical experts of Alzheimer’s Weekly also bestowed “Trial of the Year” honors on our Phase 1 clinical program. We are extremely proud of this significant and independent third-party recognition for ANAVEX 2-73 and our unique approach.

Anavex has a robust pipeline of novel drug candidates that address significant unmet medical needs for treating major devastating diseases of the Central Nervous System, such as Alzheimer’s Disease, epilepsy, depression, stroke and neuropathic pain, and various types of cancer. Our compounds are wholly owned and patent-protected.

Preclinical testing of three compounds (for the treatment of malignant melanoma, prostate cancer and epilepsy) is nearing completion. Drug candidates targeting stroke, depression and neuropathic pain, and other types of cancer are in various stages of preclinical development and may potentially enter clinical trials in the years to come.

Collaborations are extremely important to Anavex. We are proud to have strategic partnerships with leading Contract Research Organizations, compound optimization companies, labs and academic institutions. Our partners include ABX-CRO, Syntagon, Cerep, Oncodesign, Eurogenet Laboratories, FORENAP Pharma EURL, Amylgen SAS, Université Montpellier, Université Nice and Sophia Antipolis in France. These collaborations make it possible for Anavex to outsource parts of our R&D process to drive capital efficiency while maintaining control of our research initiatives and intellectual property.

Anavex is led by a seasoned team, Board and with valuable advice from a highly experienced Scientific Advisory Board. The most recent appointments to our Scientific Advisory Board include Drs. Paul Aisen, Jeffrey Cummings and Rachelle Doody, three of the world’s most highly respected clinical experts in Alzheimer’s Disease. Our team brings extensive experience in the pharmaceuticals sector, including drug discovery, drug delivery, preclinical, clinical trials, finance, business modeling and analysis, commercialization, business and corporate development and public company administration. We are confident that our team will build on the momentum created to date and continue to grow and develop Anavex as we work to combat some of the world’s most devastating diseases.

With that, we invite you to conduct further research into Anavex Life Sciences Corp. and to contact us if you have any questions. Our investor relations team can be reached by email (ir@anavex.com) or by telephone at (toll free) 1-866-505-2895 or (outside North America) + 1-416- 489-0092. If you are already a shareholder, we thank you for your loyalty and support. It is our hope that you will continue to participate in the ongoing success of Anavex Life Sciences Corp.

Sincerely,

Anavex Life Sciences Corp.

© 2007-2014 Anavex Life Sciences Corp. - All Rights Reserved.